Dana-Farber Cancer Institute, Inc. vs. Bristol-Myers Squibb Company et al.

Explore the PTAB proceeding IPR2023-00501 filed by Dana-Farber Cancer Institute, Inc. on 2023-02-06. This includes filing dates, application numbers, tech centers, patent numbers, and current case status.

Proceeding Overview

Proceeding Number

IPR2023-00501

Filing Date

2023-02-06

Accorded Filing Date

2023-02-06

Institution Decision Date

—

Last Modified Date

—

Proceeding Type

IPR

Termination Date

2023-04-18

Trial Status

Terminated-Settled

Parties & Counsel

Petitioner

Dana-Farber Cancer Institute, Inc.

Represented By

Antons, Amandaet al

Patent Owner / Respondent

Bristol-Myers Squibb Company et al.

Represented By

Maslowski, Stevenet al

Tribunal & Venue

Tribunal

Patent Trial and Appeal Board (USPTO)

Technology Center

TC 1600 - Biotechnology & Organic Chemistry

Patent Information

1 Patent Involved

Respondent Application Number 11913217

Respondent Patent Number 8008449

External Links

Espacenet

Google Patents

Respondent Inventor Alan J. Korman et al

Respondent Tech Center TC 1600 - Biotechnology & Organic Chemistry

Address and Attorney/Agent Information

127 Registered Practitioners

Power of Attorney & Correspondence

Firm / Entity Name Sterne, Kessler, Goldstein & Fox P.L.L.C. - BMS

Customer Number 115018

Address 1101 K Street, NW, 10th Floor, Washington, DC, 20005, UNITED STATES

Attorney / Agent Information

Reg #	Name	Phone
28912	Robert Sterne	202-772-8555
29021	Jorge Goldstein	202-371-2600
32705	Elliott Korsen	609-252-4741
32831	Tracy-Gene Durkin	202-371-2600
33876	Donald Featherstone	202-772-8629
33997	Michael Ray	202-772-8569
34395	Robert Millonig	202-371-2600
35239	Michael Lee	703-628-0233
35888	Henry Hadad	609-252-4825
36013	Robert Sokohl	202-371-2600
36351	Karen Markowicz	202-772-8637
36688	Eric Steffe	202-371-8625
38759	John Covert	202-371-2600
39408	Mary Vanatten	609-252-4379
39967	Eldora Ellison	202-772-8508
41306	Timothy Shea Jr	202-371-2600
42289	Donald Banowit	202-371-2600
42591	Paul Golian	609-252-4091
43447	Jason Eisenberg	202-371-2600
43689	Barry Jacobsen	609-252-5080
44757	Jeffrey Helvey	202-772-8675
45871	Mark Rygiel	202-371-2600
45986	Peter Jackman	202-371-2600
47326	Isabelle Clauss	609-252- 6254
47609	Gary Greenblatt	609-252-3850
47756	Gaby Longsworth	202-371-2600
48256	Pamela Mingo	202-371-2600
48451	Gregory Bellomy	650-260-9187
50720	Jon Wright	202-371-2600
53812	Daniel Yonan	202-371-2600
54144	Zhongmin Guo	4089389060
54179	Michelle Holoubek	202-772-8855
54463	Michael Specht	202-371-2600
54891	Hong Liu	609-252-5312
56374	Ross Hicks	202-371-2600
57170	Bing Hai	609-252-4945
57772	Lori Brandes	202-371-2600
57913	Paul Calvo	202-772-8846
58164	Kristina Kelly	202-776-5284
58403	Marsha Gillentine	202-772-8692
58885	Matthew Bodenstein	202-772-8787
59425	Kyle Conklin	202-371-2600
60167	Scott Schaller	202-371-2600
60390	Richard Coller Iii	202-772-8764
60607	Chandrika Vira	202-772-8672
60789	Cynthia Derenzo	+358-10-505-6847
60889	Salvador Bezos	202-772-8533
61205	David Holman	202-371-2600
61327	Jonathan Tuminaro	202-371-2600
61868	Dennies Varughese	202-772-8805
61908	Andrej Barbic	617-526-9427
62732	Deborah Sterling	202-772-8501
63208	Christopher O'Brien	202-772-8680
63285	Joseph Mutschelknaus	202-371-2600
63504	Ralph Powers Iii	202-772-8876
63929	Jaume Canaves	202-371-2600
64228	Graham Phero	202-772-8860
64286	Ashton Delauney	609-252-4560
64515	Daniel Gajewski	202-772-8774
64565	Teofilo Javier Jr.	617-816-0737
64681	Adam Larock	212-218-2507
64920	Julia Vom Wege	609-252-5188
65021	Christian Camarce	202-772-8895
65172	Byron Pickard	202-371-2600
65211	Michael Malek	410-533-1922
65245	Richard Crudo	202-772-8575
65326	Olga Partington	202-772-8626
65367	Jason Fitzsimmons	202-772-8701
65457	Lauren Schleh	703-836-6400
65934	Marian Silberstein	202-470-6455
66568	Branka Bogunovic	202-772-8727
66638	Jeremiah Frueauf	202-772-8506
67254	Ryan Richardson	202-772-8729
67836	Bonnie Nannenga-Combs	202-371-2600
68395	Daniel Block	202-371-2600
68504	Ji Eun Kim	202-371-2600
68658	Richard Bemben	202-371-2600
68887	Amirali Sharifi	202-772-8871
69086	Daniel Bernard	202-371-2600
69105	Nirav Desai	202-371-2600
69199	Tyler Tassone	202-371-2600
69235	Karen Wong-Chan	202-772-8647
70077	Shoshana Marvin	202-772-8850
70291	Christopher Gallo	202-371-2600
70307	Joshua Mccoy	202-772-8869
70524	Dohm Chankong	202-772-8529
70680	Sarah Leesman	202-371-2600
71185	Rebekah Holtz	202-772-8712
71909	Josephine Kim	949-422-1586
72039	Daniel Choo	202-371-2600
72126	Tyler Liu	202-772-8641
72314	Lestin Kenton Jr.	202-772-8594
72488	Yuke Wang	214-284-3876
72567	Todd Hopfinger	202-772-8696
72755	Hojung Cho	202-772-8710
72762	Bryan Hsu	202-772-8912
72981	Trevor O'Neill	202-371-2600
73112	David Haars	202-371-2600
73287	Charles Hammond	202-772-8551
73707	Matthew Smith	202-772-8503
73904	Steven Pappas	202-772-8719
74017	Robert Niemeier	309-678-6806
74290	Ian Soule	202-772-8984
74533	Alexander Covington	202-772-8749
74612	Ivy Clarice Estoesta	202-772-8686
74992	John Higgins	202-783-6040
75069	Tyler Dutton	202-772-8982
75187	Timothy Tang	202-772-8758
75234	Rola Aylo	202-772-8810
75269	Roozbeh Gorgin	202-772-8667
75349	Brian Burke	202-772-8861
76231	Todd Thurheimer	202-772-8863
76928	Hasina Ali	202-772-8978
76989	Lisa Ritchey	202-371-2600
77546	Brian Dudley	216-647-1931
77776	Zhichun Zhang	202-772-8813
78365	Wenhao Xiong	202-772-8615
78508	Louis Panzica Jr.	202-772-8954
78921	Maria Briscione	202-772-8517
79290	Michael Webb	202-772-8834
79587	Kristofer Schroder	859-991-6529
79831	Christian Berrios	317-345-2233
80131	Brittany Internoscia	908-507-3747
80152	Calvin Mendel	202-772-8511
80168	Benjamin Nagasing	202-772-8981
81060	Michael Guzzano	202-772-8646
81318	Pratibha Khanduri	202-772-8509

Proceeding Documents

Notice: refund approved NOTICE

2023-05-02 FILING PARTY: BOARD

Download

Petitioner's Request for Refund of Post-Institution Fees OTHER

2023-04-18 FILING PARTY: PETITIONER

Download

Decision Settlement Prior to Institution of Trial and Granting Joint Request to Treat Settlement Agreement as Business Confidential Information TERMINATE

2023-04-18 FILING PARTY: BOARD

Download

3001

Exhibit 3001 Exhibit

2023-04-06 FILING PARTY: BOARD

Download

Joint Request that the Settlement Agreement be Treated as Business Confidential Information Pursuant to 35 U.S.C. § 317 OTHER

2023-04-06 FILING PARTY: PETITIONER

Download

Dana-Farber Cancer Institute, Inc. vs. Bristol-Myers Squibb Company et al.

Proceeding Overview

Parties & Counsel

Petitioner

Dana-Farber Cancer Institute, Inc.

Represented By

Patent Owner / Respondent

Bristol-Myers Squibb Company et al.

Represented By

Tribunal & Venue

Patent Information

Address and Attorney/Agent Information

Power of Attorney & Correspondence

Attorney / Agent Information

Proceeding Documents

Notice: refund approved NOTICE

Petitioner's Request for Refund of Post-Institution Fees OTHER

Decision Settlement Prior to Institution of Trial and Granting Joint Request to Treat Settlement Agreement as Business Confidential Information TERMINATE

Exhibit 3001 Exhibit

Joint Request that the Settlement Agreement be Treated as Business Confidential Information Pursuant to 35 U.S.C. § 317 OTHER

Joint Motion to Terminate Pursuant to 35 U.S.C. § 317 MOTION

ORDER Granting Petitioners Motions for Admission Pro Hac Vice of Katherine A. Helm and Noah M. Leibowitz 37 C.F.R. § 42.10 c ORDER

Ono Pharmaceuticals Co., Ltd.'s Power of Attorney NOTICE

Declaration of Katherine A. Helm in Support of Motion for Admission Pro Hac Vice Exhibit

Petitioner Dana-Farber Cancer Institute, Inc.'s Unopposed Motion for Pro Hac Vice Admission of Noah M. Leibowitz MOTION

Petitioner Dana-Farber Cancer Institute, Inc.'s Unopposed Motion for Pro Hac Vice Admission of Katherine A. Helm, J.D., Ph.D. MOTION

Declaration of Noah M. Leibowitz in Support of Motion for Admission Pro Hac Vice Exhibit

Notice : Mandatory Notice NOTICE

Notice : Power of Attorney NOTICE

Notice: Notice filing date accorded NOTICE

Staerz and Bevan, Hybrid hybridoma producing a bispecific monoclonal... Exhibit

Staerz et al., Hybrid antibodies can target sites for attack by T cells,... Exhibit

Declaration of Robert J. Bloch, dated April 29, 2014, submitted on... Exhibit

U.S. Provisional Patent Application No. 60/679,466 Exhibit

Iwai et al., Involvement of PD-L1 on tumor cells in the escape from host... Exhibit

Cai et al., PD-1 ligands, negative regulators for activation of naive,... Exhibit

Daugherty, Ann L., and Randall J. Mrsny, Formulation and delivery issues... Exhibit

File History For U.S. Patent No. 8,008,449 B2 - Part 2 (pages 422-922) Exhibit

Sims et al., Effect of platelet activation on the conformation of the... Exhibit

Response to Examination report, dated April 4, 2012, in European Patent... Exhibit

GenBank® Accession No. BC074740.2, GI No. 50960296, "Homo sapiens... Exhibit

List of approved Antibodies from The Antibody Society Exhibit

File History For U.S. Patent No. 8,008,449 B2 - Part 4 (pages 1391-1980) Exhibit

European Patent No. EP2161336 B1 Exhibit

Product information for Q15116 PDCD1_HUMAN available at... Exhibit

Staerz and Bevan, Use of anti-receptor antibodies to focus T-Cell... Exhibit

Maynard, Jennifer, and George Georgiou, Antibody engineering, Annual... Exhibit

Hirano et al., Blockade of B7-H1 and PD-1 by monoclonal antibodies... Exhibit

Bindon et al., Human monoclonal IgG isotypes differ in complement... Exhibit

European Patent No. EP2161336 B1 Amended claims with annotations, dated... Exhibit

4-Antibody AG’s April 29, 2014 Arguments in Support of Opposition of... Exhibit

Declaration of Jennifer Mataraza, dated April 28, 2014, submitted on... Exhibit

U.S. Patent No. 9,580,505 Exhibit

PCT Publication No. WO 17/011666 A1 Exhibit

Ishida et al., Differential expression of PD-L1 and PD-L2, ligands for... Exhibit

Curriculum vitae of Dr. Gérard Zurawski Exhibit

File History For U.S. Patent No. 8,008,449 B2 - Part 1 (pages 1-421) Exhibit

Hoogenboom et al., Antibody phage display technology and its... Exhibit

Greenwald et al., The B7 family revisited, Annual review of immunology... Exhibit

U.S. Patent No. 9,580,507 Exhibit

Janeway CA Jr et al. Immunobiology: The Immune System in Health and... Exhibit

Vaswani, et al., Humanized antibodies as potential therapeutic drugs,... Exhibit

Ohigashi et al., Clinical significance of programmed death-1 ligand-1... Exhibit

Product information for Anti-Human PDCD1 Recombinant Antibody (PD1-17)... Exhibit

Bristol-Myers Squibb Company et al v. AstraZeneca Pharmaceuticals LP et al. Exhibit

U.S. Provisional Patent Application No. 60/748,919 Exhibit

File History For U.S. Patent No. 8,008,449 B2 - Part 3 (pages 923-1390) Exhibit

Petition : as filed PETITION

Janssen Biotech, Inc.’s April 30, 2014 Arguments in Support of... Exhibit

PCT Publication No. WO 01/14557 A1 Exhibit

Bristol-Myers Squibb Company et al v. AstraZeneca Pharmaceuticals LP et al. Exhibit

Notice : Power of Attorney NOTICE

List of Materials Considered by Dr. Gérard Zurawski Exhibit

Vaughan et al., Human Antibodies by Design, Nature Biotechnology 16 (1998) Exhibit

U.S. Provisional Patent Application No. 60/738,434 Exhibit

Novartis AG’s April 25, 2014 Notice of Opposition of EP2161336 B1 Exhibit

U.S. Patent No. 7,595,048 Exhibit

April 10, 2012 Proposed Claims, European Patent No. EP2161336 B1 Exhibit

Stern, M., and R. Herrmann, Overview of monoclonal antibodies in cancer... Exhibit

Conrath et al., Camel single-domain antibodies as modular building units... Exhibit